Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Melanoma 3Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Merkel Cell 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rectal Neoplasms 1Peritoneal Neoplasms 1Neurofibromatosis 1 1Neurofibromatoses 1Neurofibroma 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Colorectal Neoplasms 1Carcinoma, Basal Cell 1Breast Carcinoma In Situ 1Advanced Non CNS Tumors 1Adenocarcinoma 1

Interventions

Fluorouracil 71pembrolizumab 62Bevacizumab 60Oxaliplatin 59Cetuximab 59Leucovorin 56Irinotecan 55Capecitabine 31Nivolumab 23Gemcitabine 18Cisplatin 18IFL protocol 17Folfox protocol 17Cyclophosphamide 16Carboplatin 15atezolizumab 14Specimen Handling 14Paclitaxel 14Magnetic Resonance Spectroscopy 14Biopsy 14trifluridine tipiracil drug combination 12Pemetrexed 10spartalizumab 9regorafenib 9fludarabine 9Panitumumab 9130-nm albumin-bound paclitaxel 9trametinib 8durvalumab 8dehydroftorafur 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Colorectal Neoplasms × talimogene laherparepvec × Clear all
NCT03256344 2024-05-14

Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Amgen

Phase 1 Completed
36 enrolled 16 charts
BreastGastrointestinal

Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡